Unknown PHASE2 INTERVENTIONAL 1-arm NCT01678417

131I-rituximab for Relapsed or Refractory Follicular or Mantle Cell Lymphoma

A Phase II Study of 131I-rituximab for Patients With Relapsed or Refractory Follicular or Mantle Cell Lymphoma

Sponsor: Korea Cancer Center Hospital

Conditions Relapsed or Refractory Follicular Lymphoma or Mantle Cell Lymphoma

Updated 7 times since 2017 Last updated: Sep 4, 2012 Started: Jun 30, 2012 Primary completion: Jun 30, 2017 Completion: Jun 30, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Relapsed or Refractory Follicular Lymphoma or Mantle Cell Lymphoma, this trial is ongoing. The trial is conducted by Korea Cancer Center Hospital and has accumulated 7 data snapshots since 2012. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Unknown PHASE2
Sep 2024 — Sep 2025 [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE2

▶ Show 2 earlier versions

Jul 2017 — Jun 2018 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status
Jan 2017 — Jul 2017 [monthly]

Recruiting PHASE2

First recorded

Jun 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Korea Cancer Center Hospital

Data source: Korea Cancer Center Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seoul, South Korea